Seeking Alpha

Seattle Genetics (SGEN -0.9%) announces that its cancer medicine Adcetris performed well when...

Seattle Genetics (SGEN -0.9%) announces that its cancer medicine Adcetris performed well when combined with more established treatments in a phase I trial on advanced stage Hodgkin lymphoma patients. The firm says it will now move forward with a phase III clinical trial based on the positive results.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|